Hematology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant professor of pediatrics at Children's Hospital of Philadelphia discussed the role of the FOXO1 gene in T-cell persistence and exhaustion.

The invitation-only annual scientific summit, held on March 29, in New York City, brought together top scientists in cancer cell and gene therapy.

Review top news and interview highlights from the week ending May 10, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

KL003 favorably compares to platelet and neutrophil recovery rates of approved gene therapies.

Lovo-cel was approved as Lyfgenia in December 2023.

The company anticipates that initial data from the study will be announced next year.

Review top news and interview highlights from the week ending May 3, 2024.

Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

The ODAC unanimously voted in favor of the use of minimal residual disease negativity.

Testing for the presence of neutralizing antibodies is an essential step before patients can receive Beqvez.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute, discussed research on fungal infections in patients receiving HSCT and CAR-T.

The medical director of the Center for Inherited Blood Disorders discussed barriers to the widespread adoption of val-rox by the hemophilia A community.

Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin, discussed the advantages of each of the 2 modalities in the third and second line settings.

Review top news and interview highlights from the week ending April 26, 2024.

Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.

The decision was supported by the phase 3 BENEGENE-2 trial, which suggested that the Pfizer gene therapy was superior to standard of care FIX prophylaxis.

The medical director of the Center for Inherited Blood Disorders discussed the entrance of BioMarin’s val-rox into his center’s practice.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The EC’s decision comes several weeks after the FDA approved cilta-cel for a similar expanded indication.

The Assistant Professor of Medicine at Weill Cornell Medical College discussed the changing cell transplant landscape.